Recent Updates
Recently added Catalysts
MNPR Positive Sentiment

Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

Wednesday, June 14, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Monopar Therapeutics Inc. will participate in the Maxim Group’s Healthcare Virtual Conference on June 20, 2023, featuring CEO Chandler Robinson in a fireside chat. The company emphasizes its dedication to developing cancer treatments, with a pipeline that includes camsirubicin for advanced soft tissue sarcoma and other therapeutics for various cancers. This event reflects Monopar's strategy to engage with investors and raise awareness about its ongoing efforts in the biopharmaceutical field.
Price reaction · baseline $4.45 (2023-06-13 close) · hit after-hours · clean, no other MNPR news in the window
day 0 close · peak
-4.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Monopar's participation in the virtual conference showcases its commitment to transparency and investor engagement.
  • Focus on innovative treatments for cancer highlights the company's proactive approach in an essential healthcare sector.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+140%
120-day peak, hindsight
Typical move
5.5%
average across 4 past catalysts
Cash runway
~97 mo
Minimal dilution risk
Lead asset
MNPR-101-PCTA-177Lu
Phase 1 · Solid Tumor, Adult

Full Press Release Details

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a one-on-one fireside chat with Jason McCarthy, PhD, Senior Managing Director of Equity Research, at the Maxim Group’s Healthcare Virtual Conference on Tuesday June 20, 2023 at 1:30pm ET.
Fireside Chat Details:
Location: Virtual Conference
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.
Monopar Therapeutics Inc.
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

Frequently Asked Questions

What is Monopar Therapeutics focused on?

Monopar Therapeutics develops innovative cancer treatments.

When is the Maxim Group Healthcare Conference?

The conference is on June 20, 2023, at 1:30 PM ET.

Who will speak at the conference?

CEO Chandler Robinson will speak with Dr. Jason McCarthy.

What are Monopar’s key pipeline products?

Key products include camsirubicin, MNPR-101, and MNPR-202.

How can I learn more about Monopar?

Visit their website at www.monopartx.com for more information.

ShareAdd on Google
Tags: MNPR Viatris Investor Conferences Healthcare Monopar Therapeutics cancer treatments biopharmaceuticals healthcare conference
Last updated: Jun 14, 2023

Biotech snapshot

Cash runway
$105M liquidity · $1M/mo burn
~97 mo
Minimal dilution risk
Lead asset
MNPR-101-PCTA-177LuPhase 1
Solid Tumor, Adult →

Catalyst track record

+140%
best trade around MNPR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for MNPR.

See every catalyst's timing & PoA →